



BIOSIMILARS: U.S. MARKETPLACE TRENDS

Since the first biosimilars entered the U.S. marketplace in 2015, **39 products** have been approved and **22 products** have been launched, giving patients and the health system more treatment options.¹ This growth is expected to continue in the coming years, with **roughly half of all reference biologic** medications expected to face biosimilar competition in the next 5 to 10 years.²


Increased Payer Biosimilar Adoption

Payers continue to adopt biosimilars, including biosimilars or replacing originator products with biosimilars on their formularies, which can help promote competition and has the potential to lower costs. In fact, the cumulative savings in drug spend for classes with biosimilar competition is estimated to have been **\$21 billion** over the past 6 years.³

The availability of biosimilars in key therapeutic categories that currently have only 1 or a few originator biologics available helps promote competition and is a tool payers may use to help lower costs.

The Rate of Biosimilar Uptake is Generally Increasing Over Time:

As shown in the graph to the right, biosimilars have gained significant share in the majority of therapeutic areas where they have been introduced. Additionally, first-to-launch biosimilars tend to capture a greater portion of the segment compared to later entrants.⁴



How Biosimilars May Generate Savings for Payers

Biosimilar Competition May Lead to Cost Savings for Payers Across Both Reference Products and Other Biosimilars in the Same Therapeutic Category: The prices of biosimilars decreased at a negative compound annual growth rate (CAGR) of -9% to -24%. The prices of most reference products have decreased at a negative CAGR of -4% to -21%, leading to further opportunity for healthcare savings.⁵

For more information on the role biosimilars can play in helping reduce health system costs, you can view Amgen's 2022 Biosimilar Trends Report here:


www.AmgenBiosimilars.com

Amgen's Biosimilars Leadership

Amgen is dedicated to helping support a sustainable marketplace for patients and the healthcare system through our growing number of biosimilar products.

Amgen's Approach to Using Biosimilars to Improve Healthcare Sustainability

- **Providing biosimilars as lower cost treatment options** and helping to contribute to potential cost savings within the healthcare marketplace
- **Championing value-based partnerships and solutions**, including testing and helping support biosimilar adoption strategies with key stakeholders and sharing those learnings broadly
- **Investing in biosimilars education** through our annual Biosimilar Trends Report, content on AmgenBiosimilars.com, and participating in industry forums
- **Advocating for biosimilars adoption and a level playing field** and supporting reimbursement policies that promote competition among all biologics, including biosimilars



Amgen's Commitment to Biosimilars By the Numbers

40 YEARS of experience developing biologic medicines⁶

3 OF OUR BIOSIMILAR MEDICINES are included on the World Health Organization's Model List of Essential Medicines⁶

\$2B

INVESTED ACROSS

11

BIOSIMILARS^{6*}

2 of Amgen's FDA-approved biosimilars were the first oncology therapeutic biosimilars to be made available in the U.S.

They now have achieved nearly **48% and 44%** share, respectively⁴

List prices were **15% lower** than the reference product and average selling price was **12% and 13% lower**⁵

¹ Xcenda. Biosimilar approval and launch status in US. April 2022. Accessed September 15, 2022. <https://www.xcenda.com/biosimilars-trends-report>.

² Humphreys SZ. Opinion: biosimilars can aid in post-COVID-19 health care financial recovery. June 19, 2021. Accessed August 2, 2022. <https://www.centerforbiosimilars.com/view/opinion-biosimilars-can-aid-in-post-covid-19-health-care-financial-recovery>.

³ Data on file, Amgen; [1]; 2022.

⁴ Data on file, Amgen; [2]; 2022.

⁵ Data on file, Amgen; [3]; 2022.

⁶ Amgen Biosimilars. Our Approach to Pricing, Access and Affordability. <https://www.amgen.com/responsibility/our-approach-to-pricing-access-and-affordability/access-approaches-treatment-and-collaborations/biosimilars>. Accessed May 25, 2022.

* Includes AMGEVITA™ which launched in Europe. This is for informational purposes only. This is not an offer for sale. AMJEVITA™ is currently not available commercially in the United States and will not be commercially available in the United States until January 31st, 2023.